title: Detailed examination of lymph nodes improves prognostication in colorectal cancer.
abstract: Up to 30% of stage II patients with curatively resected colorectal cancer (CRC) will develop disease recurrence. We evaluated whether examination of lymph nodes by multilevel sectioning and immunohistochemical staining can improve prognostication. Lymph nodes (n = 780) from 36 CRC patients who had developed disease recurrence (cases) and 72 patients who showed no recurrence of disease for at least 5 years (controls) were analyzed. Sections of 4 levels at 200-microm interval were immunohistochemically stained for cytokeratin expression. The first level was analyzed by conventional and automated microscopy, and the 3 following levels were analyzed by automated microscopy for the presence of tumor cells. Overall, cases showed more micrometastases (3 patients) than controls (1 patient). Analysis of a second level led to the additional detection of 1 patient with micrometastases (case) and 1 patient with macrometastasis (case). Examining more levels only led to additional isolated tumor cells, which were equally divided between cases and controls. Likewise, automated microscopy resulted only in detection of additional isolated tumor cells when compared with conventional microscopy. In multivariate analysis, micrometastases [odds ratio (OR) 26.3, 95% confidence interval (CI) 1.9-364.8, p = 0.015], T4 stage (OR 4.8, 95% CI 1.4-16.7, p = 0.013) and number of lymph nodes (OR 0.9, 95% CI 0.8-1.0, p = 0.028) were independent predictors for disease recurrence. Lymph node analysis of 2 levels and immunohistochemical staining add to the detection of macrometastases and micrometastases in CRC. Micrometastases were found to be an independent predictor of disease recurrence. Isolated tumor cells were of no prognostic significance.
authors.affiliation: Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: Fania S
authors.initials: FS
authors.lastname: Doekhie
authors.forename: Wilma E
authors.initials: WE
authors.lastname: Mesker
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Kuppen
authors.forename: Gijs A
authors.initials: GA
authors.lastname: van Leeuwen
authors.forename: Hans
authors.initials: H
authors.lastname: Morreau
authors.forename: Geertruida H
authors.initials: GH
authors.lastname: de Bock
authors.forename: Hein
authors.initials: H
authors.lastname: Putter
authors.forename: Hans J
authors.initials: HJ
authors.lastname: Tanke
authors.forename: Cornelis J
authors.initials: CJ
authors.lastname: van de Velde
authors.forename: Rob A
authors.initials: RA
authors.lastname: Tollenaar
mesh_terms: D000368:Aged; D015179:Colorectal Neoplasms / Q000145:classification / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy; D016001:Confidence Intervals; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008198:Lymph Nodes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000175:diagnosis / Q000473:pathology*; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate